Lilly grants one person compassionate use of
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly and the FDA allowed one person to receive retatrutide, the company's experimental obesity candidate, through the agency's "compassionate use" program.
- Retatrutide is characterized in the source as a "highly promising" next-generation obesity drug, and the compassionate use access marks a rare single-patient route to an unapproved therapy.
Why it matters: Compassionate use is typically reserved for patients with no alternatives and serious or life-threatening conditions, so granting it for a single individual on an experimental obesity drug signals how exceptional the circumstances were — and underscores the intense demand surrounding Lilly's next-gen obesity pipeline before any approval.
